|
Orthologous residues
|
|
EphA2 (human): S897‑p, EphA2 (mouse): S898‑p, EphA2 (rat): S898‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
mutation of modification site, phospho-antibody, western blotting
|
|
Disease tissue studied:
brain cancer, glioblastoma multiforme, glioma
|
|
Relevant cell lines - cell types - tissues:
293 (epithelial), U373 MG (glial)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
human
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
Akt1 (human)
|
activation of upstream enzyme, mutation in upstream enzyme recognition motif, modification site within consensus motif
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
serum
|
|
|
|
increase
|
Serum + Fc
|
|
ephrin A1
|
serum
|
|
|
inhibit treatment-induced increase
|
Ephrin A1-Fc
|
|
SU5402
|
serum
|
|
|
no effect upon treatment-induced increase
|
|
|
|
serum
|
|
|
no effect upon treatment-induced increase
|
1-(2-Amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyr-
imidin-7-yl)-3-tert-butyl urea slight inhibition
|
|
EGF
|
|
|
|
increase
|
EGF + Fc
|
|
ephrin A1
|
EGF
|
|
|
inhibit treatment-induced increase
|
Ephrin A1-Fc
|
|
bFGF
|
|
|
|
increase
|
+ Fc
|
|
ephrin A1
|
bFGF
|
|
|
inhibit treatment-induced increase
|
Ephrin A1-Fc
|
|
SU5402
|
bFGF
|
|
|
inhibit treatment-induced increase
|
|
|
|
bFGF
|
|
|
inhibit treatment-induced increase
|
1-(2-Amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyr-
imidin-7-yl)-3-tert-butyl urea (BU)
|
|
PDGF
|
|
|
|
increase
|
PDGF + Fc
|
|
LPA
|
|
|
|
no change compared to control
|
+ Fc
|
|
ephrin A1
|
LPA
|
|
|
no change compared to control
|
Ephrin A1-Fc
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
intracellular localization
|
|
Effect of modification (process):
carcinogenesis, induced, cell motility, altered
|
|
Comments:
regulates cell migration and invasion; required for leading edge localization and cell polarization; high levels in grade IV astrocytomas (GBM samples)
|
|
Associated Diseases
|
|
Diseases:
|
Alterations:
|
Comments:
|
|
glioblastoma multiforme
|
increased
|
high levels in grade IV astrocytomas (GBM)
|
|